Medinol Group Company Research Report

Company Overview

Name: Medinol Group

Mission of the Company: Dedicated to the science of cardiovascular intervention, continuously raising the bar for revolutionary interventional cardiology products through innovative research and development.

Founded: 1992

Founders: Dr. Judith Richter and Dr. Jacob (Kobi) Richter

Key People:

Dr. Judith Richter, Co-Founder and Executive Board Co-Chairman

Dr. Jacob (Kobi) Richter, Co-Founder and Executive Board Co-Chairman

Headquarters: No information is available

Number of Employees: No information is available

Revenue: No information is available

What is the Company Known For: Medinol is known for pioneering stent system technology with over 400 patents, delivering over 2,000,000 stents. Key innovations include the revolutionary NIR stent, which provided both flexibility and robust scaffolding, expanding treatment capabilities in interventional cardiology.

Products

EluNIR™

Description: A Ridaforolimus Eluting Coronary Stent System featuring a unique CoCr framework with alternate strut widths and an elastomeric coating.

Key Features:

Superior deliverability with radiopaque spring metal tip.

Optimal flexibility and radial strength.

Consistent drug elution due to elastomeric coating.

EluNIR-PERL™

Description: An advanced Ridaforolimus Eluting Coronary Stent System with a distinct CoCr framework integrating strut variations and radiopaque markers, designed for challenging coronary anatomies.

Key Features:

Enhanced deliverability with flexible metal spring tip.

Outstanding surface integrity for uniform drug elution.

Reinforced radiopaque tip for precise placement.

IoNIR™

Description: A Drug-eluting Hybrid Scaffold.

Availability: Investigational device, restricted to investigational use only.

ChampioNIR™

Description: An Unfracturable SFA DES delivering therapeutic levels of Limus.

Availability: Investigational device, restricted to investigational use only.

Xemed

Description: A revolutionary modular device for Transcatheter Aortic Valve Replacement (TAVR).

Availability: Investigational device, restricted to investigational use only.

Microtech Sensors

Description: Sub-millimeter passive, implantable sensors.

Availability: Investigational device, restricted to investigational use only.

Recent Developments

May 23, 2024: CE approval for Medinol’s EluNIR-PERL™ Drug-Eluting Stent System.

October 7, 2024: First-in-human implantation of the ChampioNIR Drug-Eluting Peripheral Stent in Australia.

April 25, 2024: FDA approves early feasibility study for ChampioNIR™ Drug-Eluting Peripheral Stent System.

October 24, 2023: FDA approval for the next generation of the EluNIR-PERL™ Drug-Eluting Stent System.

New Partnerships: CoSo Health partners with Medinol to deliver EluNIR-PERL to hospitals across the U.S. and Brazil.

Research and Development

Medinol's R&D encompasses diverse areas such as exotic metals, drugs, polymers, and development of unique medical device manufacturing equipment. The company's clinical department is involved in global clinical trials, focusing on patient safety and advancing medicine.

Quality Control & Regulatory Affairs

Medinol employs a Quality Management System that meets high standards for safety, efficacy, and reliability. A risk-based approach is used to proactively address issues and continuously improve product quality.

Manufacturing

Medinol designs and manufactures high-quality stents using innovative techniques, providing customized solutions for improved patient outcomes. This is part of their commitment to advancing cardiovascular intervention technology.

Social Responsibility

Medinol engages in various community initiatives including supporting Holocaust survivors, the NIR School of the Heart for Middle Eastern teenagers, and integrating employees with disabilities into the workforce.